Inhibition of RhoA Prevents Cryptococcus neoformans Capsule Glucuronoxylomannan-Stimulated Brain Endothelial Barrier Disruption
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiae187 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Melissa E Munzen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Biology, University of Florida College of Dentistry, Gainesville. Hauptthemen laut MEDLINE: Cryptococcus neoformans, Blood-Brain Barrier, rhoA GTP-Binding Protein, Cryptococcosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCR NIH HHS, US National Institutes of Health, University of Florida College of Dentistry's Comprehensive Training Program in Oral Biology.
Abstract (Originalsprache)
Cryptococcus neoformans (Cn) is an opportunistic fungus that causes severe central nervous system (CNS) disease in immunocompromised individuals. Brain parenchyma invasion requires fungal traversal of the blood-brain barrier. In this study, we describe that Cn alters the brain endothelium by activating small GTPase RhoA, causing reorganization of the actin cytoskeleton and tight junction modulation to regulate endothelial barrier permeability. We confirm that the main fungal capsule polysaccharide glucuronoxylomannan is responsible for these alterations. We reveal a therapeutic benefit of RhoA inhibition by CCG-1423 in vivo. RhoA inhibition prolonged survival and reduced fungal burden in a murine model of disseminated cryptococcosis, supporting the therapeutic potential of targeting RhoA in the context of cryptococcal infection. We examine the complex virulence of Cn in establishing CNS disease, describing cellular components of the brain endothelium that may serve as molecular targets for future antifungal therapies to alleviate the burden of life-threatening cryptococcal CNS infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral Biology, University of Florida College of Dentistry, Gainesville.
- Department of Biology, Hofstra University, Hempstead, New York.
- Emerging Pathogens Institute.
- Center for Immunology and Transplantation.
- Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville.
ORCID-Profile: Luis R Martinez
Förderung
- NIDCR NIH HHS
- US National Institutes of Health
- University of Florida College of Dentistry's Comprehensive Training Program in Oral Biology
- National Institute of Allergy and Infectious Diseases
- NIAID NIH HHS
- University of Florida College of Dentistry’s Comprehensive Training Program in Oral Biology
Zitieren
APA
Munzen, M. E., Mathew, C., Enriquez, V., Minhas, A., Charles-Niño, C. L., Saytoo, D., Reguera-Gomez, M., Dores, M. R., & Martinez, L. R. (2024). Inhibition of RhoA Prevents Cryptococcus neoformans Capsule Glucuronoxylomannan-Stimulated Brain Endothelial Barrier Disruption. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae187
Vancouver
Munzen ME, Mathew C, Enriquez V, Minhas A, Charles-Niño CL, Saytoo D, et al. Inhibition of RhoA Prevents Cryptococcus neoformans Capsule Glucuronoxylomannan-Stimulated Brain Endothelial Barrier Disruption. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae187
BibTeX
@article{Munzen2024,
author = {Munzen, Melissa E and Mathew, Cristian and Enriquez, Vanessa and Minhas, Amanjeet and Charles-Niño, Claudia L and Saytoo, Durvinand and Reguera-Gomez, Marta and Dores, Michael R and Martinez, Luis R},
title = {Inhibition of RhoA Prevents Cryptococcus neoformans Capsule Glucuronoxylomannan-Stimulated Brain Endothelial Barrier Disruption},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiae187}
}
EUVIMED